Baseline characteristics in individual studies
| Study | Iida et al14 | Iida et al16 | Soga et al15 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| CLSZ | CTR | p Value | CLSZ | CTR | p Value | CLSZ | CTR | p Value | |
| Number of patients (n) | 63 | 64 | NA | 93 | 98 | NA | 39 | 39 | NA |
| Age, mean±SD | 70±9 | 70±8 | 0.94 | 72±9 | 73±8 | 0.51 | 69.8±7 | 71.6±8.1 | 0.30 |
| Male, n (%) | 19 (30.2) | 16 (25) | 0.51 | 64 (69) | 67 (68) | 1.0 | 31 (79) | 34 (87) | 0.36 |
| Diabetes, n (%) | 46 (73) | 46 (72) | 0.88 | 52 (56) | 55 (56) | 1.0 | 12 (31) | 16 (41) | 0.34 |
| Hypertension, % | 59 (94) | 59 (92) | 0.74 | 75 (81) | 80 (82) | 1.0 | 19 (49) | 19 (49) | 0.99 |
| Dyslipidaemia, n (%) | 33 (52) | 34 (53) | 0.93 | 41 (44) | 49 (50) | 0.47 | 15 (38) | 11 (28) | 0.34 |
| Current smoking, n (%) | 39 (62) | 37 (58) | 0.63 | 41 (44)* | 47 (48)* | 0.56 | 13 (33) | 17 (44) | 0.35 |
| Renal insufficiency, n (%)† | 16 (25) | 19 (30) | 0.58 | 15 (16) | 15 (15) | 1.0 | 8 (21) | 7 (18) | 0.77 |
| Coronary artery disease, n (%) | 38 (60) | 42 (66) | 0.53 | 35 (38) | 39 (40) | 0.77 | 21 (54) | 21 (54) | 0.99 |
| Preprocedure ABI, mean±SD | 0.60 ±0.23 | 0.57±0.22 | 0.43 | 0.71±0.15 | 0.66±0.14 | 0.03 | 0.59±0.12 | 0.64±0.15 | 0.13 |
| Statin use, n (%) | 19 (30) | 22 (34) | 0.29 | 30 (32) | 38 (39) | 0.37 | 10 (26) | 9 (23) | 0.79 |
| Stent, n (%) | 56 (89) | 54 (84) | 0.46 | 82 (88) | 88 (90) | 0.82 | 16 (41) | 20 (51) | 0.36 |
*Iida et al:16 combines current and prior smoking.
†Renal insufficiency definitions: Cr >2 in Iida et al;14 dialysis in Iida et al;16 Cr >1.5 in Soga et al.15
CLSZ, cilostazol; CTR, control group; NA, not applicable; ABI, Ankle Brachial Index.